Unlock instant, AI-driven research and patent intelligence for your innovation.

Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia

A composition and technology of vanadium compounds, applied in the field of amine vanadium salts, can solve the problems of toxicity of vanadium compounds, etc.

Inactive Publication Date: 2008-02-06
GENMEDICA THERAPEUTICS SL
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The main disadvantage of using vanadium compounds is their toxicity at therapeutically effective doses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia
  • Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia
  • Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Oral long-term administration of hexa(benzyl ammonium) decavanadate to the cholesterol plasma of diabetic rats horizontal effect

[0074] Oral administration of hexa(benzylammonium) decavanadate was tested to determine whether it improved dyslipidemia associated with diabetes. Induction of diabetes in rats by intravenous administration of streptozotocin resulted in greatly increased plasma concentrations of cholesterol compared to non-diabetic rats (Figure 1). Under these conditions, oral treatment with daily doses of hexa(benzyl ammonium) decavanadate significantly reduced the plasma levels of cholesterol, making no difference between control and hexa(benzyl ammonium) decavanadate-treated rats. measured difference.

Embodiment 2

[0075] Example 2 Subcutaneous long-term administration of hexa(benzyl ammonium) decavanadate on triglyceride and Effect of plasma levels of free fatty acids

[0076] Subcutaneous administration of hexa(benzylammonium) decavanadate was tested to determine whether it improves dyslipidemia associated with diabetes. Diabetes was induced in rats by intravenous administration of large amounts of streptozotocin (100 mg / kg), resulting in complete disappearance of plasma insulin and very high plasma concentrations of glucose (Fig. 2A and Fig. 2B). Induction of diabetes was also associated with substantially increased plasma concentrations of free fatty acids and triglycerides compared to non-diabetic rats (Figure 2C and Figure 2D). Under these conditions, subcutaneous treatment with different doses of hexa(benzyl ammonium) decavanadate normalized plasma concentrations of free fatty acids and triglycerides, thereby There were no measurable differences among the rats (Figure 2C and ...

Embodiment 3

[0077] Example 3 Long-term subcutaneous administration of hexa(benzyl ammonium) decavanadate on blood cholesterol levels in diabetic rats The effect of pulp level

[0078] Hexa(benzylammonium) decavanadate was administered subcutaneously to determine the effect on changes in plasma concentrations of cholesterol associated with diabetes. Diabetes was induced by intravenous administration of large amounts of streptozotocin (100 mg / kg) to rats. Experimentally induced diabetes was associated with substantially increased plasma concentrations of total and unesterified cholesterol and decreased concentrations of esterified cholesterol compared to non-diabetic rats (Fig. 3A). Diabetes did not alter HDL-cholesterol concentrations (Fig. 3B). Under these conditions, subcutaneous treatment with different doses of hexa(benzyl ammonium) decavanadate decreased the plasma concentrations of total and unesterified cholesterol and increased the concentration of esterified cholesterol. Amm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Combinations comprising vanadium (IV) / (V) compounds and pharmaceutically acceptable amines are provided. Combinations thereof are provided for the treatment or prevention of dyslipidemia, diabetes, obesity, metabolic syndrome or cardiovascular diseases.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising an amine, a combination of an amine and a pharmaceutically acceptable vanadium compound or a vanadium salt of an amine for use as an anti-dyslipidemic agent. Background technique [0002] Dyslipidemia is an umbrella term for various disorders of blood lipid levels that are associated with an increased risk of coronary heart disease (CHD), especially in patients with type 2 diabetes. Dyslipidemia is associated with elevated serum triglycerides, which can lead to pancreatitis, and is associated with elevated LDL cholesterol, or LDL cholesterol and triglycerides. This condition increases the risk of atherosclerosis, including coronary heart disease, peripheral artery disease, and cerebrovascular disease. Dyslipidemia is also associated with symptoms characterized by insulin resistance and presents as one of the cardinal features of the metabolic syndrome in type II diabetes. In fac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/24A61K31/137A61K31/28A61K31/14A61K31/132A61P3/06A61K31/13
CPCA61K31/132A61K31/137A61K31/4172A61K31/405A61K31/135A61K33/24A61K31/14A61K31/13A61K31/28A61K31/4706A61K45/06A61P3/06A61K2300/00
Inventor 亚历克·米安安东尼奥·索萨诺·奥托特卢克·马蒂·克洛泽尔
Owner GENMEDICA THERAPEUTICS SL